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Abstract9
Electrospinning was used to prepare core/shell fibers containing the active pharmaceutical ingredients10
indomethacin (IMC) or mebeverine hydrochloride (MB-HCl). The shell of the fibers was fabricated from the11
pH sensitive Eudragit S100 polymer, while the drug-loaded core was based on the mucoadhesive12
polyethylene oxide (PEO). Three different drug loadings (from 9 – 23 % w/w of the core mass) were prepared,13
and for MB-HCl two different molecular weights of PEO were explored. The resultant fibers generally14
comprise smooth cylinders, although in some cases defects such as surface particles or flattened or merged15
fibers were visible. Transmission electron microscopy showed all the systems to have clear core and shell16
compartments. The drugs are present in the amorphous physical form in the fibers. Dissolution tests found17
that the fibers can effectively prevent release in acidic conditions representative of the stomach, particularly18
for the acidic indomethacin. After transfer to a pH 7.4 medium, sustained release over between 6 and 22 h19
is observed. Given the mucoadhesive nature of the PEO core, after dissolution of the shell the fibers will be20
able to adhere to the walls of the intestinal tract and give sustained local drug release. This renders them21
promising for the treatment of conditions such as irritable bowel disease and colon cancer.22
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1. Introduction28
Electrospinning is a widely-explored technique for the fabrication of polymer/drug composites. It uses29
electrical energy to evaporate the solvent from a mixed solution of a polymer and drug. The latter is placed30
into a syringe fitted with a metal needle tip (the spinneret), and then ejected at a controlled rate towards a31
metal collector. A large potential difference is applied between the spinneret and the collector, which results32
in the rapid (ca. 10-2 s) evaporation of solvent and the formation of a solid composite in the form of one-33
dimensional fibers, typically with diameters on the nanoscale. Since it avoids the use of heat – common in34
other manufacturing processes such as spray-drying or hot-melt extrusion – electrospinning offers an35
attractive approach to handle easily-degradable active ingredients such as proteins (Jiang et al., 2014;36
Romano et al., 2016). As a result, it has attracted significant attention from pharmaceutical scientists37
(Persano et al., 2013; Repanas et al., 2016; Sridhar et al., 2015; Zamani et al., 2013).38
39
Electrospun fibers have most commonly been used to develop fast-dissolving drug delivery systems in the40
form of amorphous solid dispersions. The rapid nature of the spinning process means that the physical form41
of the fiber-forming components in solution is propagated into the solid state, and hence by preparing fibers42
from hydrophilic polymers such as poly(vinyl pyrrolidone) dramatic increases in dissolution rate can be43
achieved (Verreck et al., 2003; Yu et al., 2009). The approach can also be applied in the development of44
modified release systems, however. In this manifestation, a slow-dissolving or insoluble polymers is used as45
the filament forming matrix. For instance, Kenawy et al. produced fibers of poly(ethylene-co-vinyl acetate),46
poly(lactic acid), and the antibiotic tetracycline hydrochloride and were able to obtain sustained release over47
more than 5 days (Kenawy et al., 2002).48
49
Targeted release can also be achieved through use of a pH-sensitive polymer such as the methacrylate-based50
materials. For instance, the Evonik polymers Eudragit L100-55, L100 and S100 are insoluble below pH 5.5, 6,51
and 7 respectively, but dissolve freely at pHs above these limits. Fibers made of such materials can preclude52
drug release in the low-pH environment of the stomach where the polymer is insoluble. The drug is53
subsequently freed into solution when the fibers enter the higher-pH environment of the small intestine and54
dissolve. For instance, Eudragit L100 and L100-55 fibers loaded with diclofenac have been prepared, and55
found to effectively target the small intestine (Shen et al., 2011; Yu et al., 2014). However, it should be noted56
that simply making a fiber from a pH-sensitive polymer is not in itself sufficient to prevent release at low pH,57
because the high surface-area-to-volume ratio of the nanoscale fibers produced by electrospinning results in58
a large proportion of the incorporated drug being present at the surface, and thus easily able to diffuse into59
the release milieu (Chou et al., 2015; Pelipenko et al., 2015; Sebe et al., 2015; Zupančič et al., 2015). 60 
61
One strategy that can be used to resolve this problem is to prepare a core/shell fiber through coaxial62
electrospinning (this uses two needles, one nested inside another, and two independent working solutions).63
If the shell is drug-free and insoluble at low pH, then release in the acidic medium of the stomach should be64
avoided. Alas, this has been shown to not always be the case, and it is possible for small molecules in the65
core to diffuse through the shell even at low pH (Illangakoon et al., 2015). However, in favorable cases, the66
use of the core/shell architecture can result in systems able to give very precise targeting of drug release. For67
instance, Jin et al. used coaxial electrospinning to prepared contrast agent loaded fibers for colon-targeted68
MRI (magnetic resonance imaging) (Jin et al., 2016b). Fibers consisting of poly(ethylene oxide) (PEO) and the69
contrast agent gadolinium (III) diethylenetriaminepentaacetate hydrate (Gd(DTPA)) as the core, and Eudragit70
S100 as the shell were prepared. Dissolution studies showed minimal release at pH 1.0, and sustained release71
over 27 h at pH 7.4. The mucoadhesive properties of the fibers were also measured, and the PEO core showed72
strong adhesion forces after dissolution of the shell. This work was extended to prepare theranostic73
Gd(DTPA)/indomethacin/PEO core - Eudragit shell fibers (Jin et al., 2016a). The fibers showed very little drug74
release at pH 1.0, and sustained release at pH 7.4.75
76
In this work, we aimed to extend this previous work by preparing core/shell fibers for oral administration and77
local delivery to the colon. We report a systematic study exploring the role of key formulation parameters on78
functional performance. The literature is divided as to whether preparing a core/shell fiber with a Eudragit79
shell is sufficient to prevent release in the stomach or not, and to date there are no systematic studies which80
directly compare and contrast an acidic and a basic drug in analogous core/shell formulations to determine81
how the solubility of the drug at low pH affects the release profiles observed. In this work, we remedy this82
lack of understanding. Further, we seek to explore the effect of the molecular weight of the PEO core on the83
performance of the systems.84
85
Oral colon-specific drug delivery systems play an important role in the treatment of colonic diseases such as86
irritable bowel syndrome (IBS), colon cancer and ulcerative colitis (Nykänen et al., 2001). Local colon specific87
delivery allows the first pass effect to be bypassed, and releasing the drug at a specific site gives increased88
local bioavailability and minimizes systemic side effects (Minko, 2004). Two model drugs were selected for89
exploration: mebeverine hydrochloride and indomethacin. There are several benefits in the local delivery of90
these, and in addition they have the advantage of comprising a model basic and acidic drug, respectively.91
Chemical structures are given in Figure 1.92
93
94
95
Figure 1: The chemical structures of (a) mebeverine hydrochloride and (b) indomethacin.96
97
Mebeverine hydrochloride (MB-HCl) is an antispasmodic drug used to treat irritable bowel syndrome (IBS).98
MB-HCl works through musculotropic activity, and directly acts on the smooth muscles of the colon (Dandagi99
et al., 2009). However, traditional MB-HCl formulations have a short plasma half-life (2.5h), which means100
frequent dosing is required for successful treatment (Abdullah et al., 2011). Indomethacin (IMC) is a101
nonsteroidal anti-inflammatory (NSAID) drug used in the relief of pain and stiffness. Its mechanism of action102
involves the blocking of cyclooxygenase, which participates in the synthesis of irritant chemicals causing pain103
(Fitzpatrick, 2004). A number of studies (Hull et al., 2003; Ikawa et al., 2012; Kapitanovic et al., 2006) indicate104
that IMC can be potent in the treatment of colon cancer. However, it can also cause gastrointestinal bleeding105
and ulceration (Akhgari et al., 2013). Hence, a colon targeted formulations for IMC would be extremely106
beneficial to patients.107
108
In this work, we used coaxial electrospinning to prepare core/shell fibers with a Eudragit S100 shell and a109
PEO core, with the aim of providing colon-targeted delivery. PEO is a highly swellable and mucoadhesive110
polymer, and after the dissolution of the shell polymer was expected to result in long-lasting drug delivery.111
112
113
2. Experimental114
2.1 Materials115
Mebeverine hydrochloride (MB-HCl), indomethacin (IMC), and phosphate buffered saline (PBS) were116
purchased from Sigma-Aldrich (UK). Two different grades of polyethylene oxide (PEO) were used. PEO with117
Mw of 400,000 Da was supplied by Sigma-Aldrich (UK), and with Mw of 600,000 Da by Acros Organics (UK).118
Eudragit S100 was supplied by Evonik GmbH (Germany). Anhydrous ethanol, acetone and hydrochloric acid119
were purchased from Fisher Scientific (UK). Triton X100 and dimethylacetamide (DMAc) were obtained from120
Sigma-Aldrich (UK). All water was deionized prior to use.121
122
2.2 Solutions for electrospinning123
A shell solution was prepared from 13.5% w/v Eudragit S100 (ES100) dissolved in ethanol and DMAc (2 : 8124
v/v). Core solutions were made up in a mixture of ethanol and water (7 : 3 v/v). To aid the spinning process,125
1 % v/v acetone and 0.1 % v/v Triton-X 100 were added (Jin et al., 2016b). A series of solutions was prepared126
as detailed in Table 1.127
128
Table 1: The core solutions for coaxial electrospinning.129
Solution PEO Mw
/ 106 Da
PEO conc
/ % w/v
Drug conc/
mg/mL
Final wt% of
drug in the core
Final wt% of
drug in the fiber
MB1 0.6 2.5 2.5 9.09 0.36
MB2 0.6 2.5 5 16.67 0.71
MB3 0.6 2.5 7.5 23.08 1.06
MB4 0.4 3 3 9.09 0.42
MB5 0.4 3 6 16.67 0.84
MB6 0.4 3 9 23.08 1.26
IMC1 0.4 3 3 9.09 0.42
IMC2 0.4 3 6 16.67 0.84
IMC3 0.4 3 9 23.08 1.26
130
Two syringe pumps (KDS100, Cole-Parmer, UK) were employed to independently drive the two working131
fluids. Solutions were loaded into 5 mL syringes, with care taken to avoid bubbles, and these were then132
mounted onto the syringe pumps. The coaxial spinneret was supplied by Linari Engineering SRL (Italy), with133
the inner and outer needles having external/internal diameters of 0.83/0.51 and 1.83/1.37 mm, respectively.134
The spinneret was connected to the syringes using plastic tubing. A high voltage power supply (HCP 35-135
35000, FuG Elektronik GmbH, Germany) was connected to the tip of the needle. A flat metal collector was136
wrapped with aluminum foil and connected to the grounded electrode. The electrospinning process was137
carried out under ambient conditions at 23 ± 2 °C and 48 ± 12 % relative humidity (RH), at an applied voltage138
of 10.6 kV. The flow rate for the core solution was 0.3 mL/h, and for the shell solution 1.5 mL/h. The distance139
from the needle tip to the collector was 20 cm. After collection, fibers were stored in a desiccator over140
phosphorous pentoxide prior to analysis.141
142
2.3 Characterisation143
2.3.1 Electron microscopy144
The fibers were first assessed using a scanning electron microscope (Quanta 200, FEI, Netherlands). Prior to145
examination, samples were sputter coated with a thin layer of gold to render them conductive. The average146
fiber diameter was quantified from 100 different locations in SEM images, using the ImageJ software. For147
transmission electron microscopy (TEM), fibers were directly electrospun onto TEM grids. Images were148
recorded using a CM 120 Bio-Twin instrument (Philips/FEI Corporation, Netherlands).149
150
2.3.2 Differential scanning calorimetry151
Differential scanning calorimetry (DSC) analyses were conducted on a Q2000 instrument (TA Instruments,152
USA). Samples of 4 – 5 mg were accurately weighed into T-zero hermetic aluminum pans, which were153
subsequently sealed and the lids pinholed. The samples were first heated from 25 to 120 °C, and154
subsequently cooled to 25 °C. A second heating step was then carried out from 25 to 180 °C. All DSC155
experiments used a heating rate of 10 °C/min, under a nitrogen purge of 50 mL/min.156
157
2.3.3 X-ray diffraction158
X-ray diffraction (XRD) data were acquired using a MiniFlex 600 diffractometer (Rigaku, Japan) with Cu Kα 159 
radiation (λ = 1.5418 Å) at 40 kV and 15 mA. Patterns were recorded over the 2θ range 5 to 60° at a scan 160 
speed of 5°/min.161
162
2.3.4 Fourier transform infrared spectroscopy163
Fourier transform infrared (IR) spectra were recorded using a Spectrum 100 spectrometer (PerkinElmer, USA)164
fitted with an attenuated total reflectance accessory. The samples were scanned over the range 650 − 4000 165 
cm−1, with resolution of 1 cm−1.166
167
2.3.5 In vitro dissolution studies168
250 mg of fibers were placed in a metallic sinker. The fiber-loaded sinker was then placed in a buffer solution169
under 50 rpm continuous stirring at 37 ± 0.5 °C. In vitro drug dissolution tests were carried out in 150 mL pH170
1.2 hydrochloric acid solution for 2 h, before the fiber-loaded sinkers were transferred to 150 mL of pH 7.4171
phosphate buffered saline (PBS) for 22 h. At periodic intervals, 3 mL aliquots were withdrawn from the172
dissolution medium. The medium was refreshed with 3 mL of preheated fresh buffer solution in order to173
maintain a constant volume and ensure sink conditions. The drug concentrations in the aliquots were174
determined using UV spectrometry (6305 spectrophotometer; Jenway, UK), following construction of an175
appropriate calibration curve. The detection wavelengths were set at 263 nm for MB-HCl and 266 nm for176
IMC. Experiments were conducted in triplicate and results are reported as mean ± S.D.177
178
2.3.6 Molecular modelling179
Molecular modelling was implemented using the HyperChem software (v8.0.10). The structures of180
mebeverine and indomethacin were first drawn in ChemDraw Professional v15, and a PEO decamer181
constructed to represent the software. These were then individually imported in HyperChem, hydrogens182
explicitly included, and a trial 3D structure based on preset bond angles generated. Preliminary geometric183
minimization was performed with the MM+ forcefield using bond-dipole interactions for the non-bonded184
electrostatic interactions, and running cycles using a Polak-Ribiere conjugate gradient method until the root185
mean square (RMS) gradient reached 0.02 kcal/(Å mol). A full energetic minimization then followed using the186
AMBER3 forcefield. Here, the distance-dependent dielectric constant was assigned a value of 1, and the 1-4187
scale factors as 0.5 for both electrostatic and van der Waals repulsions. Minimization was undertaken with188
the Polak-Ribiere conjugate gradient method until the RMS gradient reached 0.001 kcal/(Å mol). No cut-offs189
were applied with either process, and in both contributions from bond stretching/compressing, bond angle190
deformations, torsional strain, van der Waals repulsions, H-bonding and electrostatic repulsions were all191
considered. Once models had been constructed for the drugs and PEO, combinations of these were merged192
to create drug-polymer composites, which then underwent the same minimization processes.193
194
3. Results195
3.1 Fiber morphology196
The compositions of the fibers prepared are given in Table 1, and SEM images are presented in Figure 2.197
198
Figure 2: SEM images of (a) MB1; (b) MB2; (c) MB3; (d) MB4; (e) MB5; (f) MB6; (g) IMC1; (h) IMC2; and (i) IMC3.199
200
For all the formulations, clear fibers can be seen, although the morphologies are somewhat irregular. The201
MB1 – 3 systems, prepared with 600 kDa PEO, appear increasingly ribbon-like as the drug concentration202
increases from 9 to 23 % w/w. This trend is also seen for the MB4 – 6 fibers (made with 400 kDa PEO), and203
in the high-loading MB6 sample the fibers are clearly merged. No such trends are visible with the IMC204
materials. In all cases, a small number of particles can be observed on the surface of the formulations. The205
fiber diameters are summarised in206
Table 2.207
208
Table 2: A summary of the fiber diameters.209
Fiber Fiber diametera
/ nm
Approx. core thicknessb
/ nm
Approx. shell thicknessb
/ nm
MB1 770 ± 370 1110 770
MB2 1100 ± 550 540 860
MB3 770 ± 240 270 265
MB4 910 ± 460 450 1250
MB5 1190 ± 410 1375 1130
MB6 1270 ± 530 1205 1005
IMC1 930 ± 420 780 1270
IMC2 820 ± 590 330 390
IMC3 740 ± 410 255 870
a Measured from the SEM images in Figure 2.210
b Estimated from the mean values in the TEM images in Figure 3211
212
The diameters are all around 1 µm. There are no clear trends in size for MB1 – 3. For MB4 – 6 the size213
increases with the drug loading, while with the IMC fibers the opposite trend is observed and the diameters214
decrease with increasing drug loading. These observations can presumably be explained by changes in the215
viscosity and conductivities of the solutions upon the addition of active ingredient.216
217
TEM images are presented in Figure 3. A clear core/shell structure is visible in all cases, despite some218
inhomogeneities in the fiber diameters and morphologies. This demonstrates that the arrangement of219
materials in the spinneret has been successfully propagated into the fiber products. The thicknesses of the220
core and shell compartments are summarised in Table 2; because of the small sample size, there are some221
differences between the values obtained and the overall diameters determined from SEM. The latter are222
much more accurate, since they are calculated on the basis of more than 100 data points.223
224
Figure 3: TEM images of (a) MB1; (b) MB2; (c) MB3; (d) MB4; (e) MB5; (f) MB6; (g) IMC1; (h) IMC2; and (i) IMC3.225
226
3.2 Physical form and component compatibility227
The physical form of the drug in the fibers was investigated using X-ray diffraction (XRD) and differential228
scanning calorimetry (DSC). XRD results are given in Figure 4.229
230
(a) (b)
(c)
Figure 4: XRD data for the raw materials and fibers, showing: (a) the starting materials; (b) the MB-HCl formulations; and, (c) the IMC231
fibers. Peaks marked * correspond to the sample holder.232
The pure drugs are both clearly crystalline materials, as evidenced by the presence of a large number of233
distinct Bragg reflections in their diffraction patterns. Both grades of PEO are semi-crystalline, with two broad234
reflections at 19 and 23°. ES100 is an amorphous material, and therefore only broad humps are observed in235
its pattern. The MB fibers all show a complete absence of Bragg reflections in their XRD patterns, and hence236
it can be concluded that the drug and PEO have been rendered into the amorphous form through237
electrospinning. The fibers exist as amorphous solid dispersions, as has been reported previously by a number238
of authors (Illangakoon et al., 2014; Jin et al., 2016a; Lopez et al., 2014; Zamani et al., 2013). The same is true239
for the IMC1 and IMC2 fibers. The picture is more complex for IMC3, and it appears that some crystalline PEO240
may be present in this formulation, given the presence of broad peaks at 20 and 24°.241
242
(a) (b)
(c)
Figure 5: DSC data for the raw materials and fibers, showing: (a) the starting materials; (b) the MB-HCl formulations; and, (c) the IMC243
fibers. Data are shown from the second heating cycle.244
245
The DSC data (Figure 5; second heats are shown) concur well with the findings from XRD. MB-HCl is a246
crystalline material with a melting endotherm at 135 °C, as is IMC (which melts at 161 °C). The former is247
consistent with the literature melting point for MB-HCl (Illangakoon et al., 2014), while the latter is consistent248
with the γ-polymorph of IMC (Surwase et al., 2013). Both grades of PEO (0.4M and 0.6M) are semi-crystalline 249 
materials with melting points at 64 °C and 65 °C, respectively. ES100 displayed a gradual change in baseline250
from around 90 to 160 °C, likely to be because of its glass transition at around 143 °C (Jin et al., 2016a).251
Melting endotherms are not visible in any of the MB-HCl formulations, suggesting MB-HCl is amorphous in252
all the fibers. Similar findings are noted for IMC: none of the IMC formulations show any melting endotherms,253
and thus the fibers appear to be amorphous solid dispersions. All the fiber formulations exhibit a broad shift254
at around 140 °C, which may be due to the glass transition of ES100 in line with previous work (Jin et al.,255
2016a).256
257
There is a small disconnect in the data for IMC3, where the DSC data indicates a fully amorphous system258
while the XRD suggests there might be some crystalline PEO remaining. This arises because the DSC data are259
from the second heating cycle; the samples were first heated from room temperature to 120 °C to remove260
any residual water and allow other events to be clearly seen. This will not affect any crystalline IMC or MB-261
HCl which might have been present, since their melting points are above this temperature, but any crystalline262
PEO will have melted during this heat. There is evidence from the first heating cycle (data not shown) of a263
very broad endotherm centered at ca. 75 °C which may be consistent with PEO melting, but this cannot be264
clearly distinguished from dehydration events. We believe that crystalline PEO present at the start of the DSC265
experiment did not recrystallize during the subsequent cooling/heating cycles, and thus no melt endotherm266
is seen. Alternatively, it could be that very poorly crystalline PEO is present in IMC3 even after reheating, but267
the melt endotherms are very broad and so cannot be discerned from the baseline. Overall therefore, the268
DSC and XRD data together clearly demonstrate that the formulations comprise amorphous solid dispersions,269
except for IMC3 where a small amount of crystalline PEO is thought to be present.270
271
IR spectra are shown in Figure 6. The raw materials are presented first, in Figure 6(a). The spectrum of MB-272
HCl contains a broad peak at ca. 2450 cm-1, corresponding to N+–H stretching. There are further bands at273
1717 cm-1 (C=O stretching), 1510 cm-1 (C=C groups in the benzene rings), and a series of bands around 2950274
cm-1 (aromatic and aliphatic C–H stretching).The spectrum of Eudragit S100 showed characteristic bands at275
1726 cm-1 (C=O stretching vibrations) and 1150 cm-1 (corresponding to C-O stretching). The PEO materials276
exhibit bands at ca. 2875 cm-1, arising from aliphatic C-H stretching, and at 1093 cm-1 from the C-O-C groups.277
Finally, IMC possesses particularly distinct bands at just below 3000 cm-1 (C-H stretches) and 1689 and 1713278
cm-1 (C=O groups).279
280
281
(a) (b)
(c)
282
Figure 6: IR spectra of (a) the raw materials; (b) the MB-HCl fibers; and (c) the IMC-loaded materials.283
284
As would be expected, the drug-loaded fibers have spectra which largely comprise composites of their raw285
materials. However, there are some differences between the spectra of the pure drug and polymer and those286
of the drug-loaded fibers. For all the MB-HCl containing fibers, the characteristic band of MB-HCl at 2475 cm-287
1 (N+–H stretch) is absent. This situation was also described by Illangakoon and co-workers in their work on288
MB-HCl loaded PVP and Eudragit fibers (Illangakoon et al., 2014). The disappearance of this peak could be289
explained by partial proton transfer from the MB-HCl to other components of the fibers, but given the low290
drug content in the fibers this absence may simply be a result of the limit of detection of the instrument (this291
peak also cannot be seen in physical mixtures made with the same proportions of ingredients as the fibers,292
where no interactions should be present). The 1717 cm-1 (C=O stretching) peak of MB-HCl is also shifted to293
1724 – 1726 cm-1, while the peak at 1510 cm-1 (which is still visible in physical mixtures; data not shown)294
cannot be seen in the fiber spectra. In the IMC case, the C=O bands have shifted to 1607 and 1724 cm-1,295
merging with peaks from the PEO 0.6M. These changes could indicate the formation of intermolecular296
interactions, but this cannot be determined with certainty owing to the low drug loading of the systems.297
298
Since it did not prove possible to confirm the presence of intermolecular interactions by IR spectroscopy, we299
constructed some simple molecular models to gain further insight. The energies of mebeverine, IMC, and a300
PEO decamer were first minimized, with values given in Table 3. Next, we combined the energy-minimized301
structures of mebeverine or IMC and PEO to create drug polymer complexes, and minimized the energies of302
these complexes (Table 3). The geometric preferences for PEO-IMC and PEO-indomethacin are given in303
Figure 7. Calculation of the difference (ΔE) between the total steric energy of the PEO-drug complexes and 304 
the sum of the total steric energies of the individual molecules provides some insight into the intermolecular305
interactions present. In both cases, ΔE is negative, confirming the presence of favourable interactions (van 306 
der Waals and H-bonding) between the drug and polymer (see Table 3).307
308
Table 3: The energetics of the optimised geometries in the PEO-drug composites. The electrostatic contribution was found to be 0 in309
all cases.310
Species
Energy / kcal mol-1
Bond-
stretching
Bond
angle Torsional
van der
Waals
H-
bonding Total ΔEa
IMC 0.6280 13.3723 7.1101 3.1252 -1.53E-05 24.2356 -
Mebeverine 1.3441 6.7667 3.1217 10.7141 0 21.9466 -
PEO 0.2782 1.2603 10.0032 5.5913 -0.0017 17.1313 -
PEO-IMC 0.9141 14.7566 17.8620 -2.5773 -0.0187 30.9367 -10.4303
PEO-mebeverine 1.5705 8.2259 13.8529 3.3278 -0.0017 26.97557 -12.1025
a ΔE = Energy of PEO-drug composite – [energy of drug + energy of PEO] 311
312
313
314
315
Figure 7: The energy-minimized structures of the PEO-IMC and PEO-mebeverine complexes.316
317
3.3 Dissolution studies318
Dissolution experiments were performed in an HCl solution at pH 1.2 for 2h, after which the fibers were319
transferred to a pH 7.4 buffer for another 22h. The results are depicted in Figure 8.320
321
(a) (b)
(c)
Figure 8: In vitro release profiles for (a) MB1, MB2, and MB3, made with PEO 0.4M; (b) MB4, MB5, and MB6, prepared with PEO322
0.6M; and, (c) IMC1, IMC2, and IMC3, made with PEO 0.4M.323
The release profiles are all relatively similar: there is initially a small amount of release in the acidic buffer,324
after which there is relatively rapid release for the next 6 – 22 h. It is clear that the ES100 coating effectively325
prevents release below pH 7. After 8h, the IMC systems have generally reached a plateau, but release326
continues after this time for IMC1 and the MB-HCl systems. A summary of the release data is given in Table327
4.328
329
330
331
Table 4: A summary of some key parameters from in vitro dissolution experiments.332
Fiber Release after 2 h / % Release after 8 h / % Max. extent of release / %
MB1 8.2 ± 2.9 94.6 ± 7.1 95.7 ± 3.7
MB2 19.4 ± 1.5 80.3 ± 4.8 88.2 ± 5.5
MB3 6.8 ± 0.6 62.0 ± 6.9 79.3 ± 5.6
MB4 12.6 ± 3.4 89.4 ± 6.5 94.9 ± 3.4
MB5 7.4 ± 1.6 81.7 ± 10.0 84.7 ± 12.4
MB6 14.3 ± 3.6 68.6 ± 6.5 79.2 ± 2.1
IMC1 1.2 ± 0.3 66.5 ± 5.9 83.5 ± 4.6
IMC2 1.3 ± 0.7 65.1 ± 5.7 68.1 ± 4.8
IMC3 1.1 ± 1.0 78.7 ± 5.3 82.6 ± 6.1
333
As would be expected, the IMC fibers release much less of their drug loading in the HCl buffer than the MB-334
HCl analogues. This is a result of IMC being an acidic drug, which has minimal solubility at pH 1.2, while the335
basic MB-HCl is more soluble here. The US Pharmacopoeia states that for delayed release dosage forms, less336
than 10% of the incorporated drug should be released in the acidic media. Other than MB2, MB4 and MB6,337
all the materials meet this specification. There are no clear trends between the drug release at pH 1.2 and its338
loading or the molecular weight of PEO used. All the formulations exhibit some drug particles at their surfaces339
in SEM (see Figure 2), which might be expected to contribute to release at low pH where the ES100 shell is340
not soluble; however, not all show appreciable release at pH 1.2. Thus, the presence of these defects is not341
thought to be of great importance.342
343
After 6 h in a pH 7.4 phosphate buffer, between 62 and 94.6 % of the incorporated drug has been released344
for MB-HCl. For IMC the range is 65.1 – 78.7 %. In the MB-HCl case, it appears that an increase in the drug345
content reduces the amount of drug released after 8 h, and this trend is still observed at the 24 h timepoint346
(see Table 3). This might be explained considering the basic nature of the drug, and the fact that as its w/w347
content in the fibers increases there is less polymer present to aid solubilisation in neutral conditions. The348
molecular weight of PEO used does not appear to make any appreciable difference to the release profiles.349
350
Considering the IMC data, it can be seen that IMC2 releases less drug than the other two formulations after351
24 h. It is not clear why this arises, but may be the result of there being much increased solubilisation from352
the PEO excipient in the core of IMC1 (9.09 % IMC), and the relatively high solubility of the indomethacin at353
pH 7.4 in IMC3 (23.08 % IMC). It may be that in IMC2 both of these dissolution enhancing effects are354
attenuated by the intermediate proportions of both drug and polymer.355
356
Attempts were made to analyse the data with the Korsmeyer-Peppas equation (data not shown). In a number357
of cases, there were insufficient datapoints below 60 % release for this to be meaningful, but where analysis358
could be attempted the results were clearly non-linear plots. This can be ascribed to the Korsmeyer-Peppas359
equation assuming a uniform distribution of active ingredient throughout the formulation, which is clearly360
not the case for the core-shell fibers prepared in this work.361
362
4. Discussion363
This work builds on the earlier findings of Jin et al. (Jin et al., 2016a), who reported core/shell364
PEO/indomethacin/Gd(DTPA)-Eudragit materials and used these to simultaneously delivery IMC as a model365
drug, and Gd(DTPA) for MRI imaging. Similar to this work, they find minimal release of the drug (< 10 %) at366
pH 1.2, and then sustained release over the next 8 – 29 h. Jin used PEOs with molecular weights of 600 and367
1000 kDa in their work, and here we extend this to show that PEO of 400 and 600 kDa can be used to prepare368
drug-loaded core/shell fibers with a pH sensitive exterior.369
370
There have been a number of reports recently concerning Eudragit-based fibers, with some also employing371
core/shell architectures. The majority of these studies show minimal release at low pH, even when using372
monolithic Eudragit L100 or S100 fibers (Aguilar et al., 2015; Illangakoon et al., 2014; Karthikeyan et al., 2012;373
Shen et al., 2011; Yu et al., 2013a; Yu et al., 2013b). In general, these studies have employed acidic or non-374
ionisable but highly insoluble drugs, which perhaps goes some way to explaining the efficiency of monolithic375
Eudragit-based fibers – intuitively, a significant proportion of release would be expected at low pH if the drug376
is soluble in those conditions, given the very high surface area of the fibers will lead to much of the drug377
being present at the fiber surface. Illangakoon et al. have recently reported the preparation of fibers with a378
Eudragit S100 shell, and a 5-fluorouracil-loaded core (Illangakoon et al., 2015). Regardless of the polymer379
used for the core, these systems showed appreciable amounts of release at pH 1, which was ascribed to the380
relatively high solubility of the drug under these conditions, and also its low molecular weight helping it to381
permeate through pores in the fiber shell and into solution.382
383
In this work, we sought to understand in more detail how the acidic or basic nature of the incorporated drug,384
and the molecular weight of the PEO core, affect release from core/shell PEO/Eudragit fibers. The fibers385
prepared here indicate that, when working with larger molecular weight drugs (466 g mol-1 for MB-HCl and386
358 g mol-1 for IMC, as compared to 131 g mol-1 for 5-fluorouracil), the production of fibers with a Eudragit387
S100 sheath can be effective in reducing drug release. It is clear that the basic drug MB-HCl is freed to a388
greater extent in the initial, low-pH, phase of the release experiment than the acidic IMC, but drug release is389
always < 20 % whereas in Illangakoon’s work values up to ca. 80 % were observed (Illangakoon et al., 2015).390
Hence, although the ionisability of the drug does influence the release profiles, even with a basic drug it is391
possible to largely prevent release in the low pH conditions of the stomach. The molecular weight of the PEO392
in the core does not appear to have any major effect on the release profile, and hence there is scope to use393
a wide range of different grades of this polymer in the core.394
395
In terms of the fibers’ potential for direct exploitation as medicines, the drug loadings (at around 0.4 – 1.25396
% w/v) are rather too low for application: for MB-HCl a typical treatment regimen is 135 mg three times daily,397
while that of IMC might be 20 – 40 mg three times daily. Further work is thus required to increase the loading398
in order to yield suitable formulations for clinical use; this will form the focus of our future work.399
400
Overall, it is clear from the data presented in this work that these types of formulations have potential for401
colon-targeted delivery if the active ingredient is chosen with care. The mucoadhesive nature of the PEO core402
(explored in detail in previous work by Jin, and found to be preserved after electrospinning and dissolution403
of the shell ES100 (Jin et al., 2016b)) should permit the formulations to adhere to the intestinal wall after404
dissolution of the Eudragit shell, thereby permitting long-term delivery of either MB-HCl or IMC. Local action405
on the intestinal wall is required for MB-HCl to have efficacy, and would also be beneficial for IMC in the406
treatment of colon cancer. Therefore, we believe these formulations may offer new modalities for the407
treatment of irritable bowel syndrome or cancer.408
409
5. Conclusions410
In this work, we report the preparation of a series of nine new formulations, six of mebeverine hydrochloride411
and three of indomethacin. These comprise electrospun fibers with a pH-sensitive Eudragit S100 shell and a412
drug-loaded polyethylene oxide (PEO) core. The fibers are found to be largely cylindrical, with smooth413
surfaces in general, although some particles at the surface and flattened or merged fibers are visible.414
Transmission electron microscopy was employed to confirm that all the fibers have clear core/shell415
structures. The drugs are found to be distributed in the amorphous physical form in the formulations.416
Dissolution tests revealed that the fibers are able to effectively preclude drug release in a pH 1.2417
environment, particularly in the case of the acidic drug indomethacin. Sustained release over ca. 6 – 22 h418
then ensues at pH 7.4. Given the mucoadhesive nature of the PEO core, the core of the fibers will have the419
ability to adhere to the wall of the intestinal tract after dissolution of the shell, providing long-term local420
delivery of either indomethacin or mebeverine. These formulations could hence offer new treatments for421
irritable bowel syndrome or colon cancer, where local drug application is required.422
423
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